Africa; Burkina Faso; Developing Countries; Epidemiology; Malaria; Nigeria; Parasitic Diseases; Public Health; Uganda; Global Health; Infectious Disease Medicine
Public Health Interests
Child health; Clinical Trials; Developing Countries (health); Epidemiology Methods; Genetic epidemiology; Global Health; Human genetic data; Immune functions; Infectious Disease; Malaria; Parasitology; Pregnancy
Professor Parikh’s research interests focus on translational studies of malaria in sub-Saharan Africa. Dr. Parikh focuses upon several aspects of malaria: early host immune responses to infection, human genetics, and treatment. Current projects include: (1) understanding host factors affecting response to artemisinin-based antimalarial therapies using a combination of individual and population-based pharmacologic approaches to inform treatment guidelines; 2) characterizing the impact of host genetic and transcriptional variability in early immune responses to malaria; and 3) understanding the impact of the HIV epidemic on the treatment of malaria in co-endemic regions. Dr. Parikh has ongoing projects in several African countries, including Uganda, Burkina Faso, and Nigeria.
Specialized Terms: Translation research in malaria; Pharmacology of antimalarials; HIV-malaria co-infection; Host response to malaria infection; Innate immunity to malaria
Extensive Research Description
1) Antimalarial Therapy in the context of pregnancy, growth/development, and HIV coinfection in Uganda
Major Goal: To assess the pharmacokinetics and pharmacodynamics of artemisinin-combination therapies and their impact upon efficacy and drug resistance in vulnerable populations
2) Innate Immune Responses in Populations with Differing Susceptibility to Malaria in Burkina Faso
Major Goal: Through the study of early transcriptional and functional cellular responses in two ethnic groups with differing susceptibility to malaria, we will identify the key innate pathways which underlie this differential ability to control parasitemia
3) Antimalarial-Antiretroviral Drug Interaction studies in Nigeria, Tanzania, and Malawi
4) Dynamic Malaria Modelling in conjunction with the Galvani group
Antiretroviral choice may affect malaria outcomes in children.
Antiretroviral choice may affect malaria outcomes in children; Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Clin Infect Dis. 2016 May 3. pii: ciw291. [Epub ahead of print]
Biochemical and immunological mechanisms by which sickle cell trait protects against malaria
Gong L, Parikh S, Rosenthal PJ, Greenhouse B. Biochemical and immunological mechanisms by which sickle cell trait protects against malaria. Malar J. 2013 Sep 11;12(1):317.
Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. The Journal of Infectious Diseases. 2013 Jun 1;207(11):1646-54
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.
Tarning J, Zongo I, Some F, Romba N , Parikh S, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clinical Pharmacology and Therapeutics 2012; 91(3):497-505.
Experimental Malaria Infection Triggers Early Expansion of Natural Killer Cells.
Kim CC, Parikh S, Sun JC, Myrick A, Lanier LL, Rosenthal PJ, DeRisi JL. Experimental Malaria Infection Triggers Early Expansion of Natural Killer Cells. Infection and Immunity 2008; 76(12): 5873-5872
In vitro metabolism of piperaquine is primarily mediated by CYP3A4.
Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012: 42(11): 1088-95. PMID: 22671777.
Pharmacokinetics of artemisinin-combination therapies in Ugandan children.
Mwesigwa J*, Parikh S*, Clark T, Njama-Meya D, Rosenthal P, Aweeka F. “Pharmacokinetics of artemisinin-combination therapies in Ugandan children”, Antimicrobial Agents and Chemotherapy 2009; 54(1):52-9.
Impact of the method of G6PD deficiency assessment in genetic association studies of malaria susceptibility.
Johnson MK, Dorsey G, Clark TD, Roenthal PJ, Parikh S. Impact of the method of G6PD deficiency assessment in genetic association studies of malaria susceptibility. PLoS One 2009; 4(9): e7246
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications. for malaria treatment in Africa.
5. Parikh S, Quedraogo JB, Goldstien JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: Implications. for malaria treatment in Africa. Clinical Pharmacology and Therapeutics 2007; 82(2): 197-203
- Parikh S, Gut J, Istvan E, Goldberg DJ, Havlir D, Rosenthal PJ. Antimalarial activity of HIV-1 protease inhibitors. Antimicrobial Agents and Chemotherapy 2005; 49(7): 2983-2985.
Full List of PubMed Publications
- Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, Ouedraogo JB, Borrmann S, Mwai L, Nsanzabana C, Price RN, Dahal P, Sambol NC, Parikh S, Nosten F, Ashley EA, Phyo AP, Lwin KM, McGready R, Day NP, Guerin PJ, White NJ, Barnes KI, Tarning J: Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Med. 2017 Jan; 2017 Jan 10. PMID: 28072872
- Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S: Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infect Dis. 2016 Oct; 2016 Dec 15. PMID: 28018925
- Hobbs CV, Gabriel EE, Kamthunzi P, Tegha G, Tauzie J, Petzold E, Barlow-Mosha L, Chi BH, Li Y, Ilmet T, Kirmse B, Neal J, Parikh S, Deygoo N, Jean Philippe P, Mofenson L, Prescott W, Chen J, Musoke P, Palumbo P, Duffy PE, Borkowsky W, P1068s Study Team.: Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. PLoS One. 2016; 2016 Dec 9. PMID: 27936233
- Anwar MY, Lewnard JA, Parikh S, Pitzer VE: Time series analysis of malaria in Afghanistan: using ARIMA models to predict future trends in incidence. Malar J. 2016 Nov 22; 2016 Nov 22. PMID: 27876041
- Roh ME, Oyet C, Orikiriza P, Wade M, Mwanga-Amumpaire J, Boum Y 2nd, Kiwanuka GN, Parikh S: Screening for Glucose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Survey in Southwestern Uganda. Am J Trop Med Hyg. 2016 Nov 2; 2016 Sep 26. PMID: 27672207
- Tchaparian E, Sambol NC, Arinaitwe E, McCormack SA, Bigira V, Wanzira H, Muhindo M, Creek DJ, Sukumar N, Blessborn D, Tappero JW, Kakuru A, Bergqvist Y, Aweeka FT, Parikh S: Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. J Infect Dis. 2016 Oct 15; 2016 Jul 28. PMID: 27471317
- West N, Gyeltshen S, Dukpa S, Khoshnood K, Tashi S, Durante A, Parikh S: An Evaluation of the National Malaria Surveillance System of Bhutan, 2006-2012 as It Approaches the Goal of Malaria Elimination. Front Public Health. 2016; 2016 Aug 19. PMID: 27595095
- Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT: Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 Aug 1; 2016 May 3. PMID: 27143666
- Sambol NC, Tappero JW, Arinaitwe E, Parikh S: Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. PLoS One. 2016; 2016 May 16. PMID: 27182702
- Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N: Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother. 2015 Dec 14; 2015 Dec 14. PMID: 26666942
- Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK: Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. Antimicrob Agents Chemother. 2015 Dec; 2015 Sep 21. PMID: 26392500
- Ndeffo Mbah ML, Parikh S, Galvani AP: Comparing the impact of artemisinin-based combination therapies on malaria transmission in sub-Saharan Africa. Am J Trop Med Hyg. 2015 Mar; 2015 Jan 26. PMID: 25624402
- Greenhalgh S, Ndeffo M, Galvani AP, Parikh S: The epidemiological impact of HIV antiretroviral therapy on malaria in children. AIDS. 2015 Feb 20. PMID: 25486414
- Zongo I, Somé FA, Somda SA, Parikh S, Rouamba N, Rosenthal PJ, Tarning J, Lindegardh N, Nosten F, Ouédraogo JB: Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine. PLoS One. 2014; 2014 Aug 18. PMID: 25133389
- Murphy SC, Shott JP, Parikh S, Etter P, Prescott WR, Stewart VA: Malaria diagnostics in clinical trials. Am J Trop Med Hyg. 2013 Nov; 2013 Sep 23. PMID: 24062484